Francis Lo - 02 Jan 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief People Officer
Signature: /s/ Francis Lo by Kyle Piskel, Attorney-in-Fact
Issuer symbol: ADPT
Transactions as of: 02 Jan 2026
Net transactions value: -$37,781
Form type: 4
Filing time: 06 Jan 2026, 19:52:39 UTC
Previous filing: 07 Jan 2026
Next filing: 14 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LO FRANCIS	Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	06 Jan 2026	0001780660

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Options Exercise	$12,469	+3,125	+0.99%	$3.99	319,103	02 Jan 2026	Direct	F1
transaction	ADPT	Common Stock	Sale	$50,250	-3,125	-0.98%	$16.08	315,978	02 Jan 2026	Direct	F1, F2
holding	ADPT	Common Stock						2,500	02 Jan 2026	By You Jin Lee (spouse)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (right to buy)	Options Exercise	$0	-3,125	-2.9%	$0.000000	104,856	02 Jan 2026	Common Stock	3,125	$3.99	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2	The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3	The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.